NVAX vs. TWST, DNLI, IOVA, RLAY, ADPT, EXEL, HALO, IONS, MDGL, and ALKS
Should you be buying Novavax stock or one of its competitors? The main competitors of Novavax include Twist Bioscience (TWST), Denali Therapeutics (DNLI), Iovance Biotherapeutics (IOVA), Relay Therapeutics (RLAY), Adaptive Biotechnologies (ADPT), Exelixis (EXEL), Halozyme Therapeutics (HALO), Ionis Pharmaceuticals (IONS), Madrigal Pharmaceuticals (MDGL), and Alkermes (ALKS). These companies are all part of the "medical" sector.
Twist Bioscience (NASDAQ:TWST) and Novavax (NASDAQ:NVAX) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.
Twist Bioscience has higher earnings, but lower revenue than Novavax. Twist Bioscience is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.
Novavax received 754 more outperform votes than Twist Bioscience when rated by MarketBeat users. Likewise, 74.14% of users gave Novavax an outperform vote while only 56.69% of users gave Twist Bioscience an outperform vote.
In the previous week, Novavax had 2 more articles in the media than Twist Bioscience. MarketBeat recorded 8 mentions for Novavax and 6 mentions for Twist Bioscience. Novavax's average media sentiment score of 1.20 beat Twist Bioscience's score of 0.59 indicating that Twist Bioscience is being referred to more favorably in the media.
53.0% of Novavax shares are held by institutional investors. 3.9% of Twist Bioscience shares are held by insiders. Comparatively, 0.9% of Novavax shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Novavax has a net margin of -40.01% compared to Novavax's net margin of -69.24%. Twist Bioscience's return on equity of 0.00% beat Novavax's return on equity.
Twist Bioscience presently has a consensus price target of $42.50, suggesting a potential upside of 4.09%. Novavax has a consensus price target of $17.50, suggesting a potential upside of 14.75%. Given Twist Bioscience's higher possible upside, analysts clearly believe Novavax is more favorable than Twist Bioscience.
Twist Bioscience has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500. Comparatively, Novavax has a beta of 1.63, meaning that its share price is 63% more volatile than the S&P 500.
Summary
Novavax beats Twist Bioscience on 11 of the 18 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding NVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
